secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuwellis, Inc. (NUWE)
CIK:        0001506492
Form:       8-K
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0001140361-23-009259
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuwellis Q4 revenue up 42% YoY to $2.3M; net loss narrows to $1.9M
------------------------------------------------------------------

- Q4 revenue $2.3M (+42% YoY); full-year revenue $8.5M (+8% YoY). Gross margin 56.9% (+250 bps).
- Net loss $1.9M ($5.00/share) vs $4.3M loss prior year; includes $2.6M other income from warrant revaluation.
- Cash $18.3M, no debt; outstanding shares ~1.2M after reverse split and warrant exercises.
- Entered exclusive U.S. license for SeaStar Medical's SCD for pediatric AKI; clinical data published supporting Aquadex.
- Board increased inducement plan shares by 44,078 to 46,928 to attract talent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506492/000114036123009259/0001140361-23-009259-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506492/000114036123009259/brhc10049033_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-009259

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer